Stockscreener 앱 받기
1.80
0.55%
-0.01
시간 외 거래:
1.80
전일 마감가:
$1.81
열려 있는:
$1.8
하루 거래량:
1.70M
Relative Volume:
0.43
시가총액:
$1.22B
수익:
$711.41M
순이익/손실:
$-133.73M
주가수익비율:
-9.4737
EPS:
-0.19
순현금흐름:
$-199.99M
1주 성능:
+0.56%
1개월 성능:
+9.76%
6개월 성능:
+21.62%
1년 성능:
+78.22%
1일 변동 폭
$1.775
$1.81
1주일 범위
$1.75
$1.87
52주 변동 폭
$0.9902
$2.035
Opko Health Inc Stock (OPK) Company Profile
명칭
Opko Health Inc
전화
305-575-4181
주소
4400 BISCAYNE BLVD., MIAMI, FL
OPK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.80 | 1.22B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
514.34 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
212.40 | 152.09B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
417.66 | 34.45B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
120.51 | 34.37B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
181.39 | 32.81B | 15.41B | 1.37B | 2.11B | 7.50 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-29 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-01-24 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | 개시 | Ladenburg Thalmann | Buy |
| 2019-11-25 | 개시 | Piper Jaffray | Overweight |
| 2018-03-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-06-21 | 재확인 | Standpoint Research | Buy |
| 2016-06-03 | 개시 | Standpoint Research | Buy |
| 2016-03-31 | 재확인 | Barrington Research | Outperform |
| 2015-10-16 | 개시 | JP Morgan | Overweight |
| 2015-09-11 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-03-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2014-05-12 | 재확인 | Oppenheimer | Outperform |
| 2014-03-14 | 개시 | Oppenheimer | Outperform |
| 2013-11-13 | 재확인 | Ladenburg Thalmann | Buy |
| 2013-05-30 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-10-22 | 개시 | Barrington Research | Outperform |
| 2011-12-01 | 재확인 | Ladenburg Thalmann | Buy |
| 2011-07-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Opko Health Inc 주식(OPK)의 최신 뉴스
Zacks Research Weighs in on OPKO Health FY2027 Earnings - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for OPKO Health (NASDAQ:OPK) - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 200,000 Shares - MarketBeat
PRESS RELEASE ISSUED FEBRUARY 4, 2000 - OPKO Health, Inc.
Q2 EPS Estimates for OPKO Health Increased by HC Wainwright - MarketBeat
Chairman & CEO of OPKO Health Phillip Frost Buys More Stock - Yahoo Finance
H.C. Wainwright maintains Buy on Opko Health, $3 target By Investing.com - Investing.com Canada
OPKO Health, Entera Bio Partner on Oral Dual Agonist GLP-1 - Contract Pharma
Forecasting The Future: 6 Analyst Projections For OPKO Health - Benzinga
Quote - OPKO Health, Inc.
Opko and Entera focus on oral care for obesity and metabolic disorders - Yahoo Finance
Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld Online
OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic - BioSpace
OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia
Essential Planning LLC. Makes New $506,000 Investment in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize
OPKO Health, Entera Bio Collaborate To Develop Oral Dual GLP-1/Glucagon Therapy For Obesity - Nasdaq
Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192 Million - Dealbreaker
OPKO and Entera partner to develop obesity pill - Reuters.com
Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders - MarketWatch
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks
OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com
OPKO and Entera Bio partner on oral obesity treatment - Investing.com India
OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan
OPKO Health (NASDAQ:OPK) Earns Buy Rating from HC Wainwright - MarketBeat
OPKO Health (NASDAQ:OPK) Given "Outperform" Rating at Barrington Research - MarketBeat
Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192M - MedCity News
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK - MSN
OPKO Health (NASDAQ:OPK) Shares Gap UpStill a Buy? - MarketBeat
Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. - Barron's
Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? - Insider Monkey
HC Wainwright Reiterates Buy Rating for OPKO Health (NASDAQ:OPK) - Defense World
OPKO Health (NASDAQ:OPK) Earns Outperform Rating from Barrington Research - Defense World
10 Best Stocks Under $3 to Buy Now - Insider Monkey
H.C. Wainwright maintains $3 target on Opko Health stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $3 target on Opko Health stock - Investing.com
Opko Health’s Strategic Divestiture and Financial Outlook Justifies Buy Rating - TipRanks
Labcorp to acquire certain assets of Opko Health’s BioReference Health - Yahoo Finance
Labcorp to buy Opko unit’s cancer test assets for up to $225M - MedTech Dive
Truist remains bullish on Labcorp after ‘another nice strategic acquisition’ - Yahoo Finance
OPKO Health’s Strategic Divestiture and Focus on Core Competencies Earns Buy Rating - TipRanks
Labcorp to acquire BioReference Health assets for up to $225M By Investing.com - Investing.com Canada
Opko Health Inc (OPK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.00%
0.49%
자본화:
|
볼륨(24시간):